Nyctos 450 mg filmom obložene

Glavna informacija

  • Trgovački naziv:
  • Nyctos 450 mg filmom obložene tablete
  • Doziranje:
  • 450 mg
  • Farmaceutski oblik:
  • filmom obložena tableta
  • Sastav:
  • Urbroj: jedna filmom obložena tableta sadrži 496,3 mg valganciklovirklorida, što odgovara 450 mg valganciklovira (kao slobodne baze)
  • Tip recepta:
  • na recept, u ljekarni ograničeni recept
  • Koristi za:
  • Ljudi
  • Vrsta lijekova:
  • alopatski lijek
  • Proizveden od:
  • Lek Pharmaceuticals d.d., Ljubljana, Slovenija; Salutas Pharma GmbH, Barleben, Njemačka; Lek S.A., Varšava, Poljska

Dokument

Lokalizacija

  • Na raspolaganju u:
  • Nyctos 450 mg filmom obložene tablete
    Hrvatska
  • Jezik:
  • hrvatski

Terapeutski informacija

  • Proizvod sažetak:
  • Pakiranje: 10 tableta u blisteru, u kutiji [HR-H-901144242-01]; 30 tableta u blisteru, u kutiji [HR-H-901144242-02]; 60 tableta u blisteru, u kutiji [HR-H-901144242-03]; 90 tableta u blisteru, u kutiji [HR-H-901144242-04]; 120 tableta u blisteru, u kutiji [HR-H-901144242-05]; 60 tableta u spremniku, u kutiji [HR-H-901144242-06] Urbroj: 381-12-01/30-14-05

Druge informacije

Status

  • Izvor:
  • HALMED Agencija za lijekove i medicinske proizvode - Agency for medicinal products and medical devices of Croatia
  • Broj odobrenja:
  • HR-H-901144242
  • Datum autorizacije:
  • 08-12-2014
  • Zadnje ažuriranje:
  • 04-06-2018

Uputu o lijeku: sastav, indikacije, doziranje, nuspojave, interakcija, trudnoća, dojenje

Uputa o lijeku: Informacija za bolesnika

Nyctos 450 mg filmom obložene tablete

valganciklovir

Pažljivo pročitajte cijelu uputu prije nego počnete uzimati ovaj lijek jer sadrži Vama važne

podatke.

Sačuvajte ovu uputu. Možda ćete je trebati ponovo pročitati.

Ako imate dodatnih pitanja, obratite se svom liječniku ili ljekarniku.

Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im naškoditi, čak i ako su

njihovi znakovi bolesti jednaki Vašima.

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika. To uključuje i

svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4.

Što se nalazi u ovoj uputi:

1. Što je Nyctos i za što se koristi

2. Što morate znati prije nego počnete uzimati Nyctos

3. Kako uzimati Nyctos

4. Moguće nuspojave

5. Kako čuvati Nyctos

6. Sadržaj pakiranja i druge informacije

1. Što je

Nyctos

i za što se koristi

Nyctos pripada skupini lijekova koji izravnim djelovanjem sprečavaju rast virusa. Valganciklovir,

djelatna tvar u tabletama, u tijelu se pretvara u ganciklovir. Ganciklovir sprečava umnažanje virusa

koji se zove citomegalovirus (CMV) i njegovo prodiranje u zdrave stanice. Kod bolesnika s

oslabljenim imunološkim sustavom CMV može uzrokovati infekciju različitih organa, što može

ugroziti život bolesnika.

Nyctos se primjenjuje:

za lij

ečenje infekcija mrežnice oka uzrokovanih CMV-om kod odraslih bolesnika sa sindromom

stečenog nedostatka imuniteta (AIDS). Infekcija mrežnice oka uzrokovana CMV-om može

izazvati smetnje vida pa i sljepoću.

za sprečavanje CMV infekcija kod odraslih bolesnika i djece koji nisu zaraženi CMV-om, a koji

su primili presadak organa od osobe zaražene CMV-om.

2. Što morate znati prije nego počnete uzimati Nyctos

Nemojte uzimati Nyctos:

- ako ste alergični na valganciklovir ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6.).

- ako ste alergični na ganciklovir, aciklovir ili valaciklovir, a to su lijekovi koji se primjenjuju za

liječenje drugih virusnih infekcija

ako dojite

Upozorenja i mjere opreza

Obratite se svom liječniku ili ljekarniku prije nego uzmete Nyctos.

ako imate malen broj bijelih krvnih stanica, crvenih krvnih stanica ili krvnih pločica (malih

stanica uključenih u zgrušavanje krvi) u krvi. Vaš će liječnik provesti krvne pretrage prije

no što počnete uzimati Nyctos tablete. Za vrijeme uzimanja tableta provodit će se dodatni testovi.

ako se liječite zračenjem ili hemodijalizom

H A L M E D

08 - 12 - 2014

O D O B R E N O

ako imate tegoba s bubrezima. Liječnik će Vam možda morati propisati manju dozu lijeka i

tijekom liječenja često kontrolirati krvnu sliku.

ako trenutno uzimate kapsule ganciklovira, a liječnik Vam želi propisati Nyctos tablete. Važno je

da ne uzmete veći broj tableta od onog koji Vam je propisao liječnik jer u suprotnom postoji

opasnost od predoziranja.

Drugi lijekovi i Nyctos

Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo

koje druge lijekove, uključujući i one koje ste nabavili bez recepta.

Ako uz Nyctos istodobno uzimate i druge lijekove, kombinacija lijekova mogla bi utjecati na

količinu lijeka koja dospijeva u Vaš krvotok ili uzrokovati štetne učinke. Obavijestite liječnika ako

već uzimate lijekove koji sadrže neku od sljedećih tvari:

imipenem/cilastatin (

antibiotik

). Uzimanje ovog lijeka s lijekom Nyctos može uzrokovati

konvulzije (napadaje)

zidovudin, didanozin, lamivudin, tenofovir, abakavir, emtricitabin ili slične vrste

lijekova koji se

koriste za liječenje AIDS-a

avirin, pegilirane interferone, adefovir i entekavir, koji se koriste za liječenje hepatitisa B ili C

probenecid (

lijek protiv gihta

). Istodobno uzimanje probenecida i lijeka Nyctos može povećati

količinu ganciklovira u krvi

mofetilmikofenolat (

koristi se nakon presađivanja

vinkristin, vinblastin, adriamicin, hidroksiureju ili slične vrste

lijekova koji se koriste u

liječenju raka

cidofovir ili foskarnet koji se koriste u

liječenju virusnih infekcija

trimetoprim, trimetoprim/sulfa kombinacije i dapson (antibiotici)

pentamidin (

lijek za liječenje zaraze parazitima ili plućnih infekcija

flucitozin ili amfotericin B (

lijekovi protiv gljivica

Nyctos s hranom i pićem

Nyctos treba uzimati s hranom. Ako iz bilo kojeg razloga niste u mogućnosti jesti, svejedno trebate

uzeti svoju dozu lijeka Nyctos kao i obično.

T

rudnoća i dojenje

Ako ste trudni ili dojite, mislite da ste trudni ili planirate zatrudnjeti, posavjetujte se sa svojim

liječnikom ili ljekarnikom prije nego uzmete ovaj lijek.

Ne smijete uzimati Nyctos ako ste trudni, osim ako Vam to ne preporuči liječnik.

Uzimanje lijeka Nyctos tijekom trudnoće može naštetiti Vašem nerođenom djetetu.

Ne smijete uzimati Nyctos ako dojite. Ako Vaš liječnik želi da se počnete liječiti lijekom Nyctos,

morate prestati dojiti prije no što počnete uzimati tablete.

Žene u reproduktivnoj dobi moraju koristiti učinkovitu kontracepciju dok uzimaju Nyctos.

Muškarci čije bi partnerice mogle zatrudnjeti moraju koristiti prezervative dok uzimaju Nyctos i još

90 dana po završetku liječenja.

Upravljanje vozilima i strojevima

Nemojte voziti ni rukovati alatima ili strojevima ako osjećate omaglicu, umor, nesigurnost ili

smetenost za vrijeme uzimanja lijeka.

Obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete bilo koji lijek.

H A L M E D

08 - 12 - 2014

O D O B R E N O

3. Kako uzimati Nyctos

Uvijek uzmite ovaj lijek točno onako kako Vam je rekao Vaš liječnik ili ljekarnik. Provjerite sa

svojim liječnikom ili ljekarnikom ako niste sigurni.

Morate biti oprezni pri rukovanju tabletama. Nemojte ih lomiti niti drobiti. Progutajte ih cijele i kad

god je moguće uz hranu. Ako slučajno dodirnete oštećene tablete, dobro operite ruke sapunom i

vodom. Ako Vam prah tableta dospije u oči, isperite ih sterilnom ili čistom vodom ako nemate

sterilne.

Da biste izbjegli predoziranje, morate se pridržavati broja tableta prema uputama liječnika.

Nyctos tablete trebate, kad god je moguće, uzeti s hranom - vidjeti dio 2.

Za djecu i adolescente koji trebaju prilagoditi dozu dostupni su drugi oblici.

Odrasli:

Prevencija CMV bolesti u bolesnika s presatkom organa

Trebate početi uzimati ovaj lijek u roku od 10 dana od transplantacije.

Preporučena doza je dvije tablete JEDNOM dnevno.

Ovu dozu trebate uzimati najdulje 100 dana nakon transplantacije. Ako ste primili bubrežni

presadak, liječnik će Vam možda preporučiti da ovu dozu uzimate 200 dana.

Liječenje aktivnog CMV retinitisa u bolesnika s AIDS-om (uvodna terapija)

Preporučena doza lijeka Nyctos je dvije tablete DVAPUT dnevno tijekom 21 dana (3 tjedna).

Nemojte uzimati ovu dozu dulje od 21 dan, osim ako Vam to ne kaže liječnik, jer se može povećati

rizik od nuspojava.

Dugoročno liječenje radi sprečavanja ponovne aktivne upale u bolesnika oboljelih od AIDS-a s

CMV r

etinitisom (terapija održavanja)

Preporučena doza je dvije tablete JEDNOM dnevno. Pokušajte uzimati tablete svakoga dana u isto

vrijeme.

Liječnik će Vam reći koliko dugo trebate uzimati Nyctos. Ako se retinitis pogorša dok uzimate ovu

dozu, liječnik će Vam možda reći da ponovite uvodnu terapiju (kako je opisano u prethodnom

odlomku) ili će Vam možda dati neki drugi lijek za liječenje CMV infekcije.

Stariji bolesnici

Nyctos nije ispitivan u starijih bolesnika.

Bolesnici s bubrežnim tegobama

Ako Vam bubrezi ne rade dobro, liječnik Vam može savjetovati da uzimate manji broj tableta svakog

dana ili da ih uzimate samo određenim danima u tjednu.

Vrlo je važno

da uzimate samo onoliko

tableta koliko Vam je liječnik propisao.

Bo

lesnici s jetrenim tegobama

Valganciklovir nije ispitivan u bolesnika s jetrenim tegobama.

Primjena u djece i adolescenata:

Sprječavanje CMV bolesti u bolesnika s presatkom

Djeca trebaju početi uzimati ovaj lijek unutar 10 dana nakon presađivanja. Doza će se razlikovati od

djeteta do djeteta ovisno o njegovoj veličini, a treba je uzimati JEDANPUT na dan. Liječnik će

odrediti najbolju dozu na temelju visine, tjelesne težine i bubrežne funkcije Vašeg djeteta. Dijete

H A L M E D

08 - 12 - 2014

O D O B R E N O

treba nastaviti uzimati tu dozu tijekom najviše 100 dana. Ako je dijete primilo bubrežni presadak,

liječnik će možda savjetovati liječenje u trajanju od 200 dana.

Ako uzmete više Nyctos tableta nego što ste trebali

Ako ste uzeli ili mislite da ste uzeli više tableta no što ste trebali, odmah se javite svom liječniku ili u

bolnicu. Uzmete li previše tableta, mogu nastupiti ozbiljne nuspojave, osobito one koje zahvaćaju krv

ili bubrege. Možda će Vam biti potrebno bolničko liječenje.

Ako ste zaboravili uzeti Nyctos

Ako zaboravite uzeti tablete, uzmite propuštenu dozu čim se sjetite, a sljedeću dozu uzmite u

uobičajeno vrijeme. Nemojte uzeti dvostruku dozu da biste nadoknadili propuštene tablete.

Ako prestanete uzimati Nyctos

Ne smijete prestati uzimati lijek, osim ako Vam to ne kaže liječnik.

U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku.

4. Moguće nuspojave

Kao i svi lijekovi i ovaj lijek može uzrokovati nuspojave, iako se neće javiti kod svakoga.

Alergijske reakcije

U najviše 1 od 100 osoba može se razviti nagla i teška alergijska reakcija na valganciklovir

(anafilaktički šok).

PRESTANITE

uzimati Nyctos i prijavite se na hitni prijem u najbližu bolnicu

ako osjetite bilo koji od sljedećih simptoma:

- izbočen kožni osip koji svrbi (

koprivnjača

naglo oticanje grla, lica, usnica i usta

koje može uzrokovati poteškoće pri gutanju ili disanju

naglo oticanje šaka, stopala

gležnjeva.

Nuspojave zabilježene tijekom liječenja valganciklovirom ili ganciklovirom navedene su u nastavku:

Vrlo česte

(mogu se javiti kod više od 1 na 10 osoba):

Učin

ci na krv: smanjenje broja bijelih krvnih stanica u krvi (neutropenija), zbog čega ćete

biti podložniji infekcijama, smanjenje pigmenta u krvi koji prenosi kisik (anemija), što može

uzrokovati umor i nedostatak zraka pri vježbanju

Učinci na disanje: nedostatak zraka ili otežano disanje (zaduha)

Učinci na želudac i probavni sustav: proljev

Česte

(mogu se javiti kod najviše 1 na 10 osoba):

Učinci na krv: smanjenje broja leukocita (krvnih stanica koji se bore protiv infekcije) u krvi

(leukopenija), smanjenje broja trombocita u krvi (trombocitopenija) - što može uzrokovati

modrice i krvarenje, smanjenje broja nekoliko vrsta krvnih stanica istodobno (pancitopenija)

Učin

ci na živčani sustav: glavobolja, poteškoće sa spavanjem (nesanica), neobični okusi

(promijenjen osjet okusa), smanjena osjetljivost na dodir (hipoestezija), osjećaj bockanja ili

trnaca kože (parestezija), gubitak osjeta u šakama ili stopalima (periferna neuropatija),

omaglica, napadaji (konvulzije)

Učinci na oči: bol u očima, oticanje (edem) unutar oka, odvajanje unutarnje očne ovojnice

(odignuće mrežnice), lebdeće mrlje u vidnom polju

Učinci na uši: bol u uhu

Učinci na disanje: kašalj

Učinci na želudac i probavni sustav: mučnina i povraćanje, bol u želucu, zatvor, vjetrovi,

loša probava (dispepsija), otežano gutanje (disfagija)

Učin

ci na kožu: upaljena koža (dermatitis), svrbež (pruritus), noćno znojenje

Učinci na mišiće, zglobove i kosti: bol u leđima, bol u mišićima (mialgija) ili zglobovima

H A L M E D

08 - 12 - 2014

O D O B R E N O

(artralgija), ukočenost mišića (rigor), grčevi u mišićima

Infekcije: gljivične infekcije usta (oralna kandidijaza), infekcije uzrokovane bakterijama ili

virusima u krvi, upala staničnog tkiva (celulitis), upala ili infekcija bubrega ili mokraćnog

mjehura

Učinci na jetru: porast razine nekih jetrenih enzima, što je moguće otkriti samo krvnim

pretragama

Učinci na bubrege: promjene u normalnom radu bubrega

Učinci na tek: gubitak teka (anoreksija), gubitak tjelesne težine

Opći učinci: umor, vrućica, bol, bol u prsima, gubitak energije (astenija), opći loše osjećanje

(malaksalost)

Učinci na raspoloženje ili ponašanje: depresija, tjeskoba, smetenost, neuobičajene misli

Ma

nje česte

(mogu se javiti kod najviše 1 na 100 osoba):

Učinci na srce: promjene normalnog ritma otkucaja srca (aritmija)

Učinci na krvotok: nizak krvni tlak (hipotenzija), što može uzrokovati osjećaj ošamućenosti

ili nesvjesticu

Učinci na krv: smanjeno stvaranje krvnih stanica u koštanoj srži

Učinci na živčani sustav: tresavica ili drhtavica (tremor)

Učinci na oči: crvene, natečene oči (konjunktivitis), poremećaj vida

Učinci na uši: gluhoća

Učinci na želudac ili probavni sustav: napuhnutost trbuha, vrijedovi u ustima, upala

gušterače (pankreatitis) pri čemu možete osjetiti jaku bol u trbuhu i leđima

Učin

ci na kožu: ispadanje kose (alopecija), osip koji svrbi ili oticanje kože praćeno

svrbežom (koprivnjača), suha koža.

Učinci na bubrege: krv u urinu (hematurija), zatajenje bubrega

Učinci na jetru: povišena razina jetrenog enzima alanin aminotransferaze (što je moguće

otkriti samo krvnim pretragama)

Učinci na plodnost: neplodnost muškaraca

Učinci na raspoloženje ili ponašanje: neuobičajene promjene raspoloženja i ponašanja,

gubitak dodira sa stvarnošću, primjerice kada osoba čuje ili vidi stvari koje nisu prisutne,

uznemirenost

Rijetke (

mogu se javiti kod najviše 1 na 1000 osoba):

Učinci na krv: prestanak stvaranja svih vrsta krvnih stanica (crvenih, bijelih krvnih stanica i

krvnih pločica) u koštanoj srži

Odvaj

anje unutarnje očne ovojnice (odignuće mrežnice) dogodilo se samo u bolesnika s AIDS-om

koji su primali valganciklovira za liječenje CMV infekcije.

Dodatne nuspojave u djece i adolescenata

Nuspojave prijavljene u djece i adolescenata slične su nuspojavama prijavljenima u odraslih

bolesnika.

Prijavljivanje nuspojava

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, ljekarnika ili medicinsku

sestru. Ovo uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.

Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava navedenog u

Dodatku V

Prijavljivanjem nuspojava možete pridonijeti u procjeni sigurnosti ovog lijeka.

5. Kako čuvati Nyctos

Ovaj lijek čuvajte izvan pogleda i dohvata djece.

H A L M E D

08 - 12 - 2014

O D O B R E N O

Rok valjanosti za bočice:

Nakon prvog otvaranja: 2 mjeseca

Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici, kutiji ili

bočici iza „Rok valjanosti“. Rok valjanosti odnosi se na zadnji dan navedenog mjeseca.

Lijek ne zahtijeva posebne uvjete čuvanja.

Nikada nemojte nikakve lijekove bacati u otpadne vode ili kućni otpad. Pitajte svog ljekarnika kako

baciti lijekove koje više ne koristite. Ove mjere pomoći će u zaštiti okoliša.

6. Sadržaj pakiranja i druge informacije

Što Nyctos sadrži

Djelatna tvar je valganciklovir.

Svaka tableta sadrži 496,3 mg valganciklovirklorida, što odgovara 450 mg valganciklovira (kao

slobodne baze).

Drugi sastojci su:

Jezgra tablete:

mikrokristalična celuloza (PH101), krospovidon (vrsta A), povidon K30, stearatna kiselina 50

Film ovojnica:

Opadry Pink

15B24005:

hipromeloza (3 cP), hipromeloza (6 cP), titanijev dioksid (E171), makrogol 400, crveni željezov

oksid (E172), polisorbat 80

Kako Nyctos

izgleda i sadržaj pakiranja

Nyctos su ružičaste, ovalne, bikonveksne filmom obložene tablete (16,7 mm x 7,8 mm) s utisnutim

“J” na jednoj strani i “156” na drugoj strani.

Aluminij/PVC/aluminij/OPA blister: 10, 30, 60, 90, 120 filmom obloženih tableta.

Spremnik od polietilena visoke gustoće (HDPE) s polipropilenskim sigurnosnim zatvaračem za djecu:

60 filmom obloženih tableta.

Nositelj odobrenja za stavljanje lijeka u promet i proizvođač

Nositelj odobrenja za stavljanje lijeka u promet

Sandoz d.o.o., Maksimirska 120, Zagreb, Republika Hrvatska

Proizvođač:

Lek Pharmaceuticals d.d., Verovškova 57, Ljubljana, Slovenija

LEK S.A., Domaniewska str. 50 C, 02-672 Varšava, Poljska

Salutas Pharma GmbH, Otto-von-Guericke-Allee 1, 39179 Barleben, Njemačka

Ovaj lijek je odobren u državama članicama Europskog ekonomskog prostora (EEA) pod

sljedećim nazivima:

Nizozemska: Valganciclovir Sandoz 450 mg, tabletten

Austrija: Valganciclovir Sandoz 450 mg - Filmtabletten

Belgija: Valganciclovir Sandoz 450 mg filmomhulde tabletten

Cipar: Valganciclovir HCL Sandoz 450 mg

Češka: Valganciclovir Sandoz 450 mg potahované tablety

Danska: Valganciclovir Sandoz

H A L M E D

08 - 12 - 2014

O D O B R E N O

Estonija: Valganciclovir Sandoz

Finska: Valganciclovir Sandoz

Francuska: VALGANCICLOVIR SANDOZ 450 mg, comprimé pelliculé

Njemačka: Valganciclovir HEXAL 450 mg Filmtabletten

Grčka

:

Valganciclovir /Sandoz

Irska: Valganciclovir Rowex 450 mg Film-coated tablets

Italija: VALGANCICLOVIR SANDOZ

Latvija: Valganciclovir Sandoz 450 mg apvalkotās tabletes

Litva: Valganciclovir Sandoz 450 mg plėvele dengtos tabletės

Luksemburg: Valganciclovir Sandoz 450 mg comprimés pelliculés

Norveška: Valganciclovir Sandoz

Poljska: Valganciclovir Sandoz

Portugal: Valganciclovir Sandoz

Rumunjska: VALGANCICLOVIR SANDOZ 450 mg comprimate filmate

Slovenija: Valganciklovir Lek 450 mg filmsko obložene tablete

Španjolska: Valganciclovir Sandoz 450 mg comprimidos recubiertos con película EFG

Švedska: Valganciclovir Sandoz

Velika Britanija: Valganciclovir 450mg Film-coated Tablets

Način i mjesto izdavanja lijeka

Lijek se izdaje na recept, u ljekarni.

Ova uputa je zadnji puta revidirana u /-

H A L M E D

08 - 12 - 2014

O D O B R E N O

21-3-2019

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Nissan Chemical Europe S.A.S. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue levels (MRLs) for the active substance pyridaben in tomatoes and aubergines. An MRL proposal of 0.15 mg/kg was derived for tomatoes and aubergines which reflects the intended use of the plant protection product containing pyridaben. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the FPS Health, Food chain safety and Environment of Belgium, submitted an application to modify the existing maximum residue level (MRL) for the active substance cyprodinil in Florence fennel to accommodate the intended use in the northern Europe. The submitted data were found sufficient to derive an MRL proposal of 4 mg/kg for cyprodinil in Florence fennel. Adequate analytical methods for enforcement are availa...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 23 compounds belonging to different chemical groups. This opinion concerns eight out of the 23 compounds, which are currently authorised for use as flavours in food. The Panel concludes that the eight additives are safe for cats and dogs at the proposed use level: phenyl...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters). They are all currently authorised as flavours in food. The FEEDAP Panel was unable to perform the assessment of non‐2(c...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-3-2019

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL to the consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC.

FDA - U.S. Food and Drug Administration

16-3-2019

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Published on: Fri, 15 Mar 2019 In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion on the safety and efficacy of formic acid, ammonium formate and sodium formate as feed hygiene agents for all animal species. In this opinion, two forms of the additive sodium formate, a solid form (specified to contain ≥ 98% sodium formate (w/w)) and a liquid form (specified to contain a minimum of 15% sodium formate, a maximum of 75% free formic acid and a maxim...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC is recalling 3 repackaged lots of Losartan Tablets USP 50mg to the consumer level. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

15-3-2019

Modification of the existing maximum residue level for fluopyram in broccoli

Modification of the existing maximum residue level for fluopyram in broccoli

Published on: Thu, 14 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance fluopyram in broccoli. The data submitted in support of the request were found to be sufficient to derive MRL proposals for broccoli. Adequate analytical methods for enforcement are available to control the residues of fluopyram on the commodit...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Published on: Wed, 13 Mar 2019 The Scientific Panel on Food Additives and Flavouring (FAF) provides a scientific opinion on the safety evaluation of annatto E and an exposure assessment of the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive, taking into account new proposed uses and use levels. In 2016, the EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) adopted a scientific opinion on the safety of annatto extracts (E 160b) as a food additive....

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Published on: Fri, 08 Mar 2019 The food enzyme has three declared activities (endo‐1,3(4)‐β‐glucanase EC 3.2.1.6, endo‐1,4‐β‐xylanase EC 3.2.1.8 and cellulase (endo‐1,4‐β‐d‐glucanase EC 3.2.1.4)) and is produced with a non‐genetically modified Mycothermus thermophiloides strain by Novozymes A/S. It is intended to be used in baking and brewing processes. For the two intended uses, based on the maximum use levels recommended and individual data from the EFSA Comprehensive European Food Database, dietary e...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Published on: Tue, 12 Mar 2019 The food enzyme triacylglycerol lipase (triacylglycerol acylhydrolase, EC 3.1.1.3) is produced with a genetically modified Aspergillus niger strain LFS by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The triacylglycerol lipase food enzyme is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the fo...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Published on: Tue, 12 Mar 2019 The food enzyme glucose oxidase (β‐d‐glucose:oxygen 1‐oxidoreductase; EC 1.1.3.4) is produced with a genetically modified Aspergillus niger strain ZGL by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucose oxidase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme‐total orga...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-3-2019

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Published on: Fri, 08 Mar 2019 The food enzyme 4‐α‐glucanotransferase (1,4‐α‐d‐glucan:1,4‐α‐d‐glucan 4‐α‐d‐glycosyltransferase, EC 2.4.1.25) is produced with a non‐genetically modified Aeribacillus pallidus (previously identified as Geobacillus pallidus) strain from Amano Enzyme Inc. The food enzyme is intended to be used in baking processes and in starch processing for the production of modified dextrins. For baking processes, based on the maximum use levels recommended and individual data from the EFS...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-3-2019

Safety of ethyl lauroyl arginate (E 243) as a food additive in the light of the new information provided and the proposed extension of use

Safety of ethyl lauroyl arginate (E 243) as a food additive in the light of the new information provided and the proposed extension of use

Published on: Fri, 08 Mar 2019 The present scientific opinion deals with the evaluation of the safety of the food additive ethyl lauroyl arginate (E 243) in the light of a new interpretation of the available toxicological data and with respect to the proposed changes to the currently authorised conditions of use. Ethyl lauroyl arginate (E 243) is an already authorised food additive in the EU for use in heat‐treated meat products only, with some exceptions. The safety of ethyl lauroyl arginate (E 243) as...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-3-2019


Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

7-3-2019

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity

American Health Packaging is voluntarily recalling one lot of Valsartan Tablets, USP, 160 mg to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-Nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Resea...

FDA - U.S. Food and Drug Administration

7-3-2019

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Published on: Wed, 06 Mar 2019 The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion on Quillaia extract (E 999) when used as a food additive and the evaluation of the safety of its proposed extension of use as a food additive in flavourings. The Scientific Committee for Food (SCF) in 1978 established an acceptable daily intake (ADI) of 0–5 mg spray‐dried extract/kg body weight (bw) per day for E 999. The Joint FAO/WHO Expert Committee on Food Additives ...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Published on: Tue, 05 Mar 2019 Following a request from European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Robenz® 66G (robenidine hydrochloride (HCl)) when used as a feed additive for chickens for fattening and turkeys for fattening. The coccidiostat Robenz®66G is considered safe for chickens for fattening at the highest proposed level of 36 mg robenidine HCl/kg complete feed with a ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Safety advisory – Section 19A product not for epidural or intrathecal use

Therapeutic Goods Administration - Australia

5-3-2019

Opinion on the follow‐up of the re‐evaluation of sorbic acid (E200) and potassium sorbate (E202) as food additives

Opinion on the follow‐up of the re‐evaluation of sorbic acid (E200) and potassium sorbate (E202) as food additives

Published on: Fri, 01 Mar 2019 In this opinion, the EFSA Panel on Food Additives and Flavourings (FAF Panel) was requested by the European Commission to carry out a scientific evaluation of an extended one‐generation reproductive toxicity study (EOGRTS) to determine whether it would allow reconsideration of the temporary group acceptable daily intake (ADI) for sorbic acid (E 200) and potassium sorbate (E 202), established by the Panel on Food Additives and Nutrient Sources added to Food (ANS Panel) in 2...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-3-2019

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical

Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

26-2-2019

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Published on: Mon, 25 Feb 2019 Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the product TYFER™ (ferric tyrosine chelate) as zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breeding. The additive is safe for chickens for fattening at the maximum expected level of 200 mg TYFER™/kg complete feed; this conclusion can be extended to chickens reared for laying/breedin...

Europe - EFSA - European Food Safety Authority EFSA Journal

25-2-2019

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity

Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited.

FDA - U.S. Food and Drug Administration

25-2-2019

Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients

Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients

FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (RA). FDA has not approved this 10 mg twice daily dose for RA; this dose is only approved in the dosing regimen for patients with ulcerative colitis

FDA - U.S. Food and Drug Administration

14-2-2019

Modification of the existing maximum residue levels for mandipropamid in various crops

Modification of the existing maximum residue levels for mandipropamid in various crops

Published on: Wed, 13 Feb 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Syngenta Crop Protection B.V. and Agriculture and Horticulture Development Board (AHDB) submitted, respectively, a request to the competent national authorities in the Netherlands and United Kingdom to modify the existing maximum residue levels (MRLs) for the active substance mandipropamid in various crops. The data submitted in support of the request were found to be sufficient to derive MRL propo...

Europe - EFSA - European Food Safety Authority EFSA Journal

4-2-2019

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it’s wholly owned subsidiary, Dr Reddy’s Laboratories, Inc is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetram in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags to the hospital level in U.S.A.

FDA - U.S. Food and Drug Administration

30-1-2019

Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

Monmouth Junction, NJ, Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3) additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, to the retail (pharmacy) level. Some units from these batches have been found to have higher levels of Ibuprofen concentration.

FDA - U.S. Food and Drug Administration

26-1-2019

Safety assessment of the substance poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) for use in food contact materials

Safety assessment of the substance poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) for use in food contact materials

Published on: Fri, 25 Jan 2019 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of poly((R)‐3‐hydroxybutyrate‐co‐(R)‐3‐hydroxyhexanoate) (PHBH), CAS No 147398‐31‐0 and food contact material (FCM) substance No 1059. This biodegradable copolymer is produced by fermentation of palm oil using a genetically modified microorganism (Cupriavidus necator). Overall migration was up to 5.4 mg/kg. Oligomers are hydroxyl‐terminated or with crotyl‐ and hexenyl end‐...

Europe - EFSA - European Food Safety Authority EFSA Journal

23-1-2019

Safety evaluation of the food enzyme lysophospholipase from Trichoderma reesei (strain RF7206)

Safety evaluation of the food enzyme lysophospholipase from Trichoderma reesei (strain RF7206)

Published on: Tue, 22 Jan 2019 The food enzyme lysophospholipase (EC 3.1.1.5) is produced with the genetically modified Trichoderma reesei strain RF7206 by AB Enzymes GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The lysophospholipase food enzyme is intended to be used in starch processing for the production of glucose syrups. Residual amounts of total organic solids (TOS) are removed by the ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue level for trifloxystrobin in broccoli

Modification of the existing maximum residue level for trifloxystrobin in broccoli

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance trifloxystrobin in broccoli. The data submitted in support of the request were found to be sufficient to derive an MRL proposal for broccoli. Adequate analytical methods for enforcement are available to control the residues of trifloxystrobin o...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Landesanstalt für Landwirtschaft und Gartenbau Sachsen‐Anhalt (LSA) and Dienstleistungszentrum Ländlicher Raum Rheinpfalz (DLR), respectively, submitted a request to the competent national authority in Germany to modify the existing maximum residue levels (MRL) for the active substance aclonifen in chives, parsley, celery leaves/dill leaves, thyme/savoury and in celeriacs/turnip‐rooted celery. The ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for aminopyralid in certain cereals

Modification of the existing maximum residue levels for aminopyralid in certain cereals

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Dow AgroSciences Denmark submitted a request to the competent national authority in the United Kingdom to modify the existing maximum residue levels (MRLs) for the active substance aminopyralid in cereals. The data submitted in support of the request were found to be sufficient to derive MRL proposals for barley, rye, sorghum, millet and oats. A modification of the existing MRL of aminopyralid in wh...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-1-2019

Safety for the environment of vitamin D3 for salmonids

Safety for the environment of vitamin D3 for salmonids

Published on: Thu, 17 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) of EFSA assessed the safety for the target species and the consumer of the use of a maximum total level of 1.5 mg vitamin D3/kg feed in fish nutrition (2017). The assessment was based on data that had been provided by the Norwegian Food Safety Authority (NFSA). Since the data set provided by the NFSA did not include any new information concerning the safety for the user and the environment...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Published on: Wed, 16 Jan 2019 The additive cassia gum consists mainly of high-molecular weight polysaccharides composed primarily of a linear chain of 1,4-b-D-mannopyranose units with 1,6-linked a-D-galactopyranose units. In 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) delivered an opinion on the safety and efficacy of cassia gum in cats and dogs. The Panel concluded, based on positive findings observed in a bacterial reverse mutation test with a semi-refined cassia...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Published on: Wed, 16 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of two compounds belonging to chemical group 20 (aliphatic and aromatic mono‐ and di‐thiols and mono‐, di‐, tri‐, and polysulfides with or without additional oxygenated functional groups). 8‐Mercapto‐p‐menthan‐3‐one [12.038] and p‐menth‐1‐ene‐8‐thiol [12.085] are currently ...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Published on: Wed, 16 Jan 2019 The additive under assessment is pure benzoic acid (> 99.8%), manufactured in the form of flakes. It is intended to be used as a technological feed additive (acidity regulator) in feedingstuffs for weaned piglets and pigs for fattening, with maximum contents of 5,000 and 10,000 mg/kg complete feed, respectively. Benzoic acid is safe for weaned piglets at 5,000 mg/kg complete feed, and at 10,000 mg/kg complete feed for pigs for fattening. The use of benzoic acid in feedings...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of Deccox® (decoquinate) for chickens for fattening

Safety and efficacy of Deccox® (decoquinate) for chickens for fattening

Published on: Mon, 14 Jan 2019 Deccox®, containing decoquinate as the active substance, is a feed additive intended to be used for the prevention of coccidiosis in chickens for fattening at a dose range of 20–40 mg/kg complete feed. Decoquinate from Deccox® is safe for chickens for fattening at the highest applied concentration in complete feed of 40 mg/kg. No practically relevant interactions with other additives or veterinary drugs exist except with bentonite. Decoquinate does not have antibacterial a...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-1-2019

Setting of an import tolerance for spiromesifen in coffee beans

Setting of an import tolerance for spiromesifen in coffee beans

Published on: Mon, 14 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer CropScience submitted a request to the competent national authority in Greece to set an import tolerance for the active substance spiromesifen in coffee beans. The data submitted in support of the request were found to be sufficient to derive a maximum residue level (MRL) proposal for coffee beans. Adequate analytical methods for enforcement are available to control the residues of spiromesife...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-1-2019

Germany Black Ant 2000mg tablets (Zhansheng Weige Chaoyue Xilishi)

Germany Black Ant 2000mg tablets (Zhansheng Weige Chaoyue Xilishi)

These tablets pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level. The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass.

FDA - U.S. Food and Drug Administration

6-1-2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. The products have been found to contain visual grey particulate matter in reconstituted vials.

FDA - U.S. Food and Drug Administration

22-12-2018

Modification of the existing maximum residue level for captan in cranberries

Modification of the existing maximum residue level for captan in cranberries

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the Belgian Federal Public Service (FPS) for Health, Food chain safety and Environment, submitted an application as the competent national authority in Belgium to modify the existing maximum residue level (MRL) for the active substance captan in cranberries. The data submitted in support of the request were found to be sufficient to derive MRL proposal for cranberries. Adequate analytical methods for enforcement ...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-12-2018

Apo-Prednisone 5 mg Tablet (2018-12-18)

Apo-Prednisone 5 mg Tablet (2018-12-18)

Health Canada

17-12-2018


Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

17-12-2018


Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

14-12-2018

Statement on the safety of d‐ribose

Statement on the safety of d‐ribose

Published on: Thu, 13 Dec 2018 In 2018, the EFSA NDA Panel adopted the Scientific Opinion on the safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283 when used in a variety of food, concluding that d‐ribose is safe for the general population at intake levels up to 36 mg/kg body weight (bw) per day, but that its safety at the intended uses and use levels as proposed by the applicant could not be established. Following a request from the European Commission, the EFSA NDA Panel was aske...

Europe - EFSA - European Food Safety Authority Publications

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

7-12-2018

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Published on: Thu, 06 Dec 2018 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of propane‐1,2‐diol esters of fatty acids (E 477) when used as a food additive. The Scientific Committee on Food (SCF) in 1978 endorsed the acceptable daily intake (ADI) of 25 mg/kg body weight (bw) per day, expressed as propane‐1,2‐diol, established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1974. No adverse effects were observed in short‐t...

Europe - EFSA - European Food Safety Authority Publications

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

28-11-2018

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).

Health Canada

23-11-2018

ACT-Candesartan 4mg tablets (2018-11-23)

ACT-Candesartan 4mg tablets (2018-11-23)

Health Canada

22-11-2018

Foreign Product Alert: Black Ant King tablets, Gold Viagra 9800mg capsules, LIPRO Dietary capsules, Stree Overlord Strong tablets (pills), Vegetal Vigra capsules, ViaGro 500mg Male Enhancement capsules

Foreign Product Alert: Black Ant King tablets, Gold Viagra 9800mg capsules, LIPRO Dietary capsules, Stree Overlord Strong tablets (pills), Vegetal Vigra capsules, ViaGro 500mg Male Enhancement capsules

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients.

Health Canada

1-2-2019

Diotop 75 mg / 20 mg modified-release capsules, hard and associated names

Diotop 75 mg / 20 mg modified-release capsules, hard and associated names

Diotop 75 mg / 20 mg modified-release capsules, hard and associated names (Active substance: diclofenac/omeprazole) - Community Referrals - Art 29 - Commission Decision (2019)845 of Fri, 01 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/A-29(4)/1474

Europe -DG Health and Food Safety

17-1-2019

Holoclar (Chiesi Farmaceutici S.p.A.)

Holoclar (Chiesi Farmaceutici S.p.A.)

Holoclar (Active substance: Ex vivo expanded autologous human corneal epithelial cells containing stem cells) - Centralised - Annual renewal - Commission Decision (2019)272 of Thu, 17 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2450/R/21

Europe -DG Health and Food Safety

13-12-2018


Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Europe - EMA - European Medicines Agency

13-12-2018


Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

4-12-2018


Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance

Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance

Overview of comments received on Ibuprofen 200 – 800 mg oral use, immediate release formulations product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

4-12-2018


Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance

Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance

Overview of comments received on draft dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency